IBM has just announced a new software solution that “enables research institutions and biopharmaceutical companies across the world to integrate, store, analyze and better understand genotypic and phenotypic data for medical research and patient care.”

The gist of it is that they capture–and de-identify (a new word for the modern security-conscious HIPAA age)–data from existing hospital and research systems, store data from healthcare institutions and diagnostic labs, then centralize it all to yield the opportunity for research on steroids.